PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

Completed · Phase 1

Conditions studied: Alzheimer's Disease, Healthy

In brief

Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called \[11C\]MeS-IMPY.

Key facts

Study ID

NCT00407576

Run by

National Institute of Mental Health (NIMH)

People needed

30

Starts

2006-12-01

Last updated by the study team

2017-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Current or prior history of any alcohol or drug abuse.
• Severe systemic disease based on history and physical exam.
• Positive result on urine screen for illicit drugs.
• Laboratory tests with clinically significant abnormalities.
• Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
• Pregnancy or breast feeding.
• Claustrophobia.
• Presence of ferromagnetic metal in the body or heart pacemaker.
• History of brain disease other than Alzheimer's disease.
• Unable to lay on one's back for the PET/MRI scan.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.